share_log

Mangoceuticals | 8-K: Current report

Mangoceuticals | 8-K: Current report

Mangoceuticals | 8-K:重大事件
美股SEC公告 ·  10/01 19:35

牛牛AI助理已提取核心訊息

On October 1, 2024, Mangoceuticals, Inc., also known as MangoRx, announced the launch of its new oral Semaglutide weight loss treatment named 'Slim.' The product is now available for purchase on the company's telemedicine platform. This launch represents a significant step for MangoRx in addressing the growing global GLP-1 market, which is projected to expand from $49.3 billion in 2024 to $157.5 billion by 2035. 'Slim' is offered as an oral dissolvable tablet compounded with Vitamin B6, providing a convenient alternative to injections. MangoRx's CEO, Jacob Cohen, expressed optimism about the product's potential to meet increasing consumer demand for effective weight management solutions. The company has competitively priced 'Slim' at $299 per month, aiming to make the treatment accessible to a broad customer base. MangoRx focuses on men's health and wellness products and services, including erectile dysfunction, hair growth, hormone replacement therapies, and weight management, all available through its secure telemedicine platform.
On October 1, 2024, Mangoceuticals, Inc., also known as MangoRx, announced the launch of its new oral Semaglutide weight loss treatment named 'Slim.' The product is now available for purchase on the company's telemedicine platform. This launch represents a significant step for MangoRx in addressing the growing global GLP-1 market, which is projected to expand from $49.3 billion in 2024 to $157.5 billion by 2035. 'Slim' is offered as an oral dissolvable tablet compounded with Vitamin B6, providing a convenient alternative to injections. MangoRx's CEO, Jacob Cohen, expressed optimism about the product's potential to meet increasing consumer demand for effective weight management solutions. The company has competitively priced 'Slim' at $299 per month, aiming to make the treatment accessible to a broad customer base. MangoRx focuses on men's health and wellness products and services, including erectile dysfunction, hair growth, hormone replacement therapies, and weight management, all available through its secure telemedicine platform.
2024年10月1日,Mangoceuticals公司,也被稱爲MangoRx,宣佈推出其新的口服Semaglutide減肥治療產品' Slim'。該產品現在可以在公司的遠程醫療平台上購買。這次推出代表了MangoRx在應對不斷增長的全球GLP-1市場上邁出的重要一步,該市場預計從2024年的493億美元擴張到2035年的1575億美元。'Slim'是一種口服可溶片,配有維生素B6,爲注射提供了方便的替代方法。MangoRx的CEO Jacob Cohen對該產品滿懷樂觀,認爲它有潛力滿足消費者對有效減肥解決方案日益增長的需求。該公司已將'Slim'定價爲每月299美元,旨在讓廣泛的客戶群體能夠獲得這一治療。MangoRx專注於男性健康和健康產品及服務,包括治療勃起功能障礙、促進頭髮生長、激素替代療法以及減肥等,所有這些都可以通過其安全的遠程醫療平台獲得。
2024年10月1日,Mangoceuticals公司,也被稱爲MangoRx,宣佈推出其新的口服Semaglutide減肥治療產品' Slim'。該產品現在可以在公司的遠程醫療平台上購買。這次推出代表了MangoRx在應對不斷增長的全球GLP-1市場上邁出的重要一步,該市場預計從2024年的493億美元擴張到2035年的1575億美元。'Slim'是一種口服可溶片,配有維生素B6,爲注射提供了方便的替代方法。MangoRx的CEO Jacob Cohen對該產品滿懷樂觀,認爲它有潛力滿足消費者對有效減肥解決方案日益增長的需求。該公司已將'Slim'定價爲每月299美元,旨在讓廣泛的客戶群體能夠獲得這一治療。MangoRx專注於男性健康和健康產品及服務,包括治療勃起功能障礙、促進頭髮生長、激素替代療法以及減肥等,所有這些都可以通過其安全的遠程醫療平台獲得。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。